Tribenzyltin carboxylates as anticancer drug candidates: Effect on the cytotoxicity, motility and invasiveness of breast cancer cell lines

Anasamy T 1 , Thy CK 2 , Lo KM 3 , Chee CF 2 , Yeap SK 4 , Kamalidehghan B 5 Show all authors , Chung LY 6

Affiliations 

  • 1 Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia
  • 2 Department of Chemistry, Faculty of Science, University of Malaya, 50603, Kuala Lumpur, Malaysia
  • 3 Department of Chemistry, Faculty of Science, University of Malaya, 50603, Kuala Lumpur, Malaysia; Research Centre for Crystalline Materials, Sunway University, 47500, Petaling Jaya, Selangor Darul Ehsan, Malaysia. Electronic address: kmlo42@gmail.com
  • 4 Institute of Bioscience, Universiti Putra Malaysia, 43400, Serdang, Selangor Darul Ehsan, Malaysia
  • 5 Medical Genetics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, 1983963113, Tehran, Iran; Medical Genetics Department, National Institute for Genetic Engineering and Biotechnology (NIGEB), 1497716316, Tehran, Iran
  • 6 Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia. Electronic address: chungly@hotmail.com
Eur J Med Chem, 2017 Jan 05;125:770-783.
PMID: 27723565 DOI: 10.1016/j.ejmech.2016.09.061

Abstract

This study seeks to investigate the relationship between the structural modification and bioactivity of a series of tribenzyltin complexes with different ligands and substitutions. Complexation with the N,N-diisopropylcarbamothioylsulfanylacetate or isonicotinate ligands enhanced the anticancer properties of tribenzyltin compounds via delayed cancer cell-cycle progression, caspase-dependent apoptosis induction, and significant reduction in cell motility, migration and invasion. Halogenation of the benzyl ring improved the anticancer effects of the tribenzyltin compounds with the N,N-diisopropylcarbamothioylsulfanylacetate ligand. These compounds also demonstrated far greater anticancer effects and selectivity than cisplatin and doxorubicin, which provides a rationale for their further development as anticancer agents.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications